Explore new ideas and improve therapeutic strategies
Overcome highly pathogenic agents and multidrug-resistant bacteria
Despite the major developments of vaccines and antibiotics, infectious diseases still cause the death of about 17 million people all around the world every year. We keep facing new threats while some diseases leave us powerless while resistant bacterial strains are spreading and we are struggling to renew our therapeutic strategies.
To efficiently fight these threats, it is thus essential to:
- Prevent the spread of resistant bacteria,
- Repurpose drugs,
- Discover and develop innovative molecules.
Achieving these goals come with major scientific and technological challenges to which the Antimicrobials program contributes by developing an integrated approach that takes in account four parameters: the pathogen, the host, the disease and the therapy.
The Antimicrobials program is conducted in close partnership with other multidisciplinary programs of BIOASTER as well as with private and academic research teams.
Through collaborative projects, the Antimicrobials program focuses on three major innovation areas:
Discovering and characterising new antimicrobials
The priority is to identify antimicrobials (antibacterial, antifungal, antiviral and antiprotozoal) belonging to new classes. To achieve that goal, the program develops innovative screening and characterisation technologies. The mechanism of action of new antimicrobial compounds is deciphered using robust multiomic strategies (genomics, transcriptomics, proteomics and metabolomics). The efficacy of candidate drugs is evaluated in vitro on bacterial strains isolated from patients and in vivo by using ad hoc and robust preclinical and predictive models.
Aligning antimicrobial drug discovery with complex host-pathogen and host-drug interactions data
The aim is to develop new therapeutic or prophylactic strategies by taking into account the mechanisms that allows the pathogens to escape the host immune response (antigenic modulation, immunosuppression in sepsis, immunosenescence,…), the increased susceptibility of hosts to infections (malnutrition, microbiome alteration…) or the resistance of pathogens to antimicrobials.
To respond to these challenges, in addition to multiparametric tailor made immunoprofiling strategies, these studies combine BIOASTER multi-omic pipeline with in vitro and in vivo imaging methods.
Exploring new therapeutic approaches
BIOASTER explores alternative therapeutic approaches such as phage therapy, phytotherapy, antimicrobial peptides (first line of defense against bacteria, fungi and viruses), virulence factors and fecal microbiota transplantation. To combat emerging and re-emerging pathogens, drug repurposing or the combination of drugs (antibiotics or not) also constitute interesting therapeutic approaches.
Project example – DACCAR: prevent the antimicrobial resistances from spreading while protecting the microbial gut flora
The DACCAR (Destroy Antibiotics in Colon to Combat Antibiotic Resistance) project is performed in collaboration with the DaVolterra company. DACCAR aims at producing an innovate strategy limiting the development of multidrug resistant bacteria in the caecum and colon of patients treated with antibiotics. This strategy protecting the microbial gut flora from the secondary effects of antibiotics will contribute to the reduction of opportunistic infections, the maintainance the drug efficacy through time (especially last chance antibiotics such as carbapenems) and the reduction od antimicrobial resistance dessemination.
Antimicrobial resistance: global report on surveillance 2014, WHO, April 2014.
Innovate with BIOASTER